Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel in benign soft tissue tumor resection
NCT05082441Phase 4Unknown
- Sponsor
- Samaritan Health Services
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine extended release liposome injection in Benign soft tissue neoplasm (2 arms), sponsored by Samaritan Health Services. Primary endpoint: Opioid Use at 7 days. Status: unknown.
02
Drugs
bupivacaine extended release liposome injection
03
Conditions
Benign soft tissue neoplasm
Beyond the preview
Go deeper on NCT05082441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082441.